ELRIG appoints Del Trezise as chair
Ella Day | April 8, 2025 | Appointment | Research and Development | ELRIG, Pharmacy, R&D, drug discovery, non-profit organisation, pharma
ELRIG, a non-profit volunteer-led organisation dedicated to the drug discovery community, has appointed Del Trezise as chair of the board. He succeeds Melanie Leveridge, who completed her four-year term as chair.
He will lead ELRIG’s mission to deliver highly accessible scientific meetings and conferences. It serves a global network of over 22,000 life sciences professionals.
Since 2013, Trezise has been an avid volunteer for ELRIG acting as scientific programme chair, early career professionals work group leader, and head of the innovation work group. He has been on the ELRIG board since 2017, composed of other experts to set the organisation’s strategy and initiatives to respective groups.
Moreover, he brings 30 years of experience in academic, biotech and biopharma settings. He currently holds leadership and advisory roles at Sartorius, Axol Bioscience, Semarion and Refeyn, and previously at GSK. Additionally, he co-founded the European arm of Essen BioScience, playing a pivotal role in developing industrial-scale, live-cell imaging technology for drug discovery.
Leveridge, outgoing chair of ELRIG, and vice president of assays, profiling and cell sciences at AstraZeneca, commented: “Del is widely respected for his scientific and business leadership across biotech and pharmaceutical research and development. Over the past decade, he has helped shape ELRIG, particularly in supporting early-career professionals and startups. It has been an honour to serve as chair, and I look forward to seeing ELRIG continue to grow under Del’s guidance.”
Trezise said: “I’m excited to build on this foundation by further strengthening collaboration between our community partners through our world-class conferences and events. I look forward to working with the highly talented ELRIG board, leadership team and volunteer network in fulfilling this ambition.”
Ella Day
8/4/25
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
ANGLE’s Parsortix system used in new cancer biology research
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour …
DEBRA Research and Dermaliq Therapeutics collaborate to advance treatment for rare skin disorder
Global non-profit organisation, DEBRA Research, and clinical dermatology company, Dermaliq Therapeutics, have announced a collaboration …
